IceCure Medical Ltd (NASDAQ: ICCM) had its price target raised by analysts at Alliance Global Partners from $1.90 to $2.90. They now have a "buy" rating on the stock.
IceCure Medical Ltd. - Ordinary Shares (ICCM)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ICCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCM alerts
High impacting IceCure Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ICCM
News
- IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.MarketBeat
- IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America [Yahoo! Finance]Yahoo! Finance
- IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North AmericaPR Newswire
- IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate [Yahoo! Finance]Yahoo! Finance
- IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free RatePR Newswire
ICCM
Earnings
- 5/28/24 - In-Line
ICCM
Analyst Actions
- 3/28/25 - HC Wainwright
ICCM
Sec Filings
- 3/27/25 - Form 20-F
- 3/27/25 - Form 20-F
- 3/27/25 - Form 6-K
- ICCM's page on the SEC website